Metagenomi Inc. (MGX) - Market Cap to Net Income Ratio

Metagenomi, Inc - graphic logo of issuer MGX

The price trend reflected below, where the indicator stands at -0.30, is based on Metagenomi, Inc. (MGX) utilizing metagenomic analysis to develop innovative gene-editing tools that bypass patent restrictions. High R&D expenditures and stringent regulatory oversight create a formidable defensive barrier for the business. Despite the absence of current sales, Metagenomi, Inc. (MGX) possesses immense pricing power within the rare genetic pathology therapy segment.

MGX Metagenomi Inc.: Price to Earnings Ratio in the range 08/16/2024 - 11/16/2026

Analytical breakdowns for Metagenomi, Inc.

- price and consensus price forecast:
Summary company analysis:Metagenomi, Inc.
Original product of Metagenomi, Inc.

The P/E ratio reflects the market value of a single unit of net profit, allowing investors to assess whether an asset is overvalued or if they are facing a value trap. By analyzing the P/E level of a company, an investor can determine the ratio of market capitalization to earnings, which for Metagenomi, Inc. (MGX), conducting leading preclinical research in the US without geopolitical risks, underscores the investment value of future technological breakthroughs in DNA editing.

Competing companies

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine, Inc. EDIT|Price to Earnings Ratio silence-therapeutics.com SLN|PRQR: Price to Earnings Multiple|CDXS - Price to Earnings Ratio|Business Payback Period Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Price to Earnings Ratio|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio